HCP Medical Centre, Poznan University of Medical Sciences, Poznan, Poland.
Kardiol Pol. 2013;71(12):1287-92. doi: 10.5603/KP.2013.0325.
Functional mitral regurgitation (FMR) is known to contribute to a poor prognosis in patients with heart failure (HF). Current guidelines do not recommend cardiac surgery in patients with FMR and impaired ejection fraction due to the high procedural risk. Percutaneous techniques aimed at mitral valve repair may constitute an alternative to currently used routine medical treatment.
To provide a description of a novel percutaneous suture-based technique of direct mitral annuloplasty using the Mitralign Bident system, as well as report our first case successfully treated with this method.
A deflectable guiding catheter is advanced via the femoral route across the aortic valve to the posterior wall of the ventricle. A nested deflectable catheter is advanced through the guide toward the mitral annulus that allows the advancement of an insulated radiofrequency wire to cross the annulus. The wire is directed across the annulus in a target area that is 2-5 mm from the base of the leaflet into the annulus, as assessed by real-time 3D transoesophageal echocardiography. After placement of the first wire, another wire is positioned using a duel lumen bident delivery catheter, which provides a predetermined separation between wires (i.e. 14, 17 or 21 mm). Each wire provides a guide rail for implantation of sutured pledget implants within the annulus. Two pairs of pledgets are implanted, one pair in each of the P1 and P3 scallop regions of the posterior mitral annulus. A dedicated plication lock device is used to provide a means for plication of the annulus within each pair of the pledgets, and to retain the plication by delivering a suture locking implant. The plications result in improved leaflet coaptation and a reduction of the regurgitant orifice area.
A 60-year-old female with diagnosed dilated cardiomyopathy, concomitant FMR class III and congestive HF was successfully treated with the Mitralign Bident system. Two pairs of pledgets were implanted resulting in an improvement of transoesophageal echocardiographic parameters, including proximal isovelocity surface area radius (0.7 cm to 0.4 cm), effective regurgitant orfice area (0.3 cm² to 0.1 cm²) and mitral regurgitant volume (49 mL to 10 mL).
Percutaneous mitral annuloplasty with the Mitralign Bident system is feasible. Future clinical trials are needed to assess its safety and efficacy.
功能性二尖瓣反流(FMR)已知会导致心力衰竭(HF)患者预后不良。由于程序风险高,目前的指南不建议对射血分数降低的 FMR 患者进行心脏手术。旨在修复二尖瓣的经皮技术可能是目前常规药物治疗的替代方法。
提供一种使用 Mitralign Bident 系统的新型经皮缝线直接二尖瓣环成形术的描述,并报告我们用这种方法成功治疗的首例病例。
通过股动脉途径推进可弯曲的引导导管穿过主动脉瓣至心室后壁。将嵌套的可弯曲导管推进通过引导导管朝向二尖瓣环,允许推进绝缘射频线穿过环。通过实时 3D 经食管超声心动图评估,将线引导到距瓣叶基部 2-5 毫米的目标区域,穿过环。放置第一根线后,使用双腔双叉输送导管定位另一根线,该导管在两根线之间提供预定的间隔(即 14、17 或 21 毫米)。每根线都为在环内植入缝合瓣状植入物提供了导轨。植入两对瓣状植入物,一对植入后二尖瓣环的 P1 和 P3 扇区。专用的折叠锁定装置用于提供在每对瓣状植入物内折叠环的手段,并通过输送缝线锁定植入物来保留折叠。折叠导致瓣叶对合改善和反流口面积减小。
一名 60 岁女性患有扩张型心肌病,并发 FMR III 级和充血性 HF,成功接受了 Mitralign Bident 系统治疗。植入两对瓣状植入物导致经食管超声心动图参数改善,包括近端等速表面积半径(0.7 厘米至 0.4 厘米)、有效反流口面积(0.3 平方厘米至 0.1 平方厘米)和二尖瓣反流量(49 毫升至 10 毫升)。
Mitralign Bident 系统的经皮二尖瓣环成形术是可行的。需要进行未来的临床试验来评估其安全性和疗效。